Olysio (simeprevir) / J&J, Medivir 
Welcome,         Profile    Billing    Logout  
 36 Diseases   5 Trials   5 Trials   637 News 
6 Trials

   

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Olysio (simeprevir) / J&J, Medivir
NCT01727323 / 2010-021337-31: A Study to Assess the Safety, Tolerability and Efficacy of TMC435 Along With Pegylated Interferon Alpha-2a (Pegasys) and Ribavirin (Copegus) Triple Therapy in Chronic Hepatitis C Genotype-1 Infected Patients Co-infected With Human Immunodeficiency Virus-Type 1

Active, not recruiting
3
109
US, Canada, Europe
TMC435, Pegylated interferon alpha-2a, Ribavirin
Janssen Research & Development, LLC, Janssen R&D Ireland, Tibotec Pharmaceuticals
Hepatitis C Virus Genotype-1
08/13
08/13
NCT02256176 / 2014-003446-27: Efficacy and Safety Study of Simeprevir in Combination With Sofosbuvir in Subjects With Chronic Genotype 4 Hepatitis C Virus Infection

Not yet recruiting
3
40
Europe
Simeprevir, TMC435, Sofosbuvir
Janssen R&D Ireland, Janssen R&D Ireland
Chronic Hepatitis C, Genotype 4 Chronic Hepatitis C
11/15
01/16
NCT05616598: Effect of New Oral Treatment for Hepatitis C Virus on Seminal Parameters

Completed
2/3
200
RoW
Sofosbuvir +daclatasvir+ simeprevir+Ribavirin
Benha University
Male Infertility, HCV
11/22
12/22
SWITCH-1, NCT02583685: Switching Regimen in Treating Cirrhotic HCV GT1b Subjects

Recruiting
2
160
RoW
PR4 + LDV/SOF + ASV 4 wk, Pegasys®, Copegus®, Harvoni®, Sunvepra®, PR4 + LDV/SOF + SMV 4 wk, OLYSIO®, PR4 + LDV/SOF + ASV 6 wk, PR4 + LDV/SOF + SMV 6 wk, PR4 + LDV/SOF + ASV 8 wk, PR4 + LDV/SOF + SMV 8 wk, PR4 + LDV/SOF + ASV 12 wk, PR4 + LDV/SOF + SMV 12 wk
Humanity and Health Research Centre, Beijing 302 Hospital, Nanfang Hospital of Southern Medical University
Chronic Hepatitis C Infection
10/22
12/22
NCT05728619: HTMC0435 and Temozolomide in Treating Patients With Small Cell Lung Cancer

Recruiting
1b/2
64
RoW
HTMC0435, Temozolomide
Shanghai Yidian Pharmaceutical Technology Development Co., Ltd.
Recurrent Extensive Stage Small Cell Lung Carcinoma
08/24
10/24
CTR20200573: Phase I/II clinical trial evaluating HTMC0435 tablets in patients with advanced malignant solid tumors

Recruiting
1/2
42
China
HTMC0435 - Shanghai Huilun
Shanghai Huilun Life Technology Co., Ltd./Shanghai Yidian Pharmaceutical Technology Development Co., Ltd.
Avanced malignant solid tumors
 
 

Download Options